Source: International Congress 2016 – Airway biomarkers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Paolo Montuschi (Rome, Italy), Giuseppe Santini, Nadia Mores, Claudio Luchinat, Leonardo Tenori, Alessia Vignoli, Francesco Macagno, Leonello Fuso, Tim Higenbottam, Paolo Montuschi. Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on electronic nose and NMR metabolomic breathprints in patients with COPD. Eur Respir J 2016; 48: Suppl. 60, 1075

Member's Comments

No comment yet.

Related content which might interest you: The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effects of combining tiotropium and salmeterol/fluticasone propionate on airway dimensions in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 The influence of type of inhalation device on adherence of COPD patients to inhaled medication Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effect of tiotropium on exhaled breath temperature in patients with COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Effect of carbocysteine lysine salt on frequency of exacerbations in COPD patient treated with or without inhaled steroids Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014